2017 - CIRTA


This page contains exclusive content for the member of the following sections: TTS, ITA. Log in to view.

7- Infections and Other Lessons Learned after IntestineTransplantation

32.9 - Adenoviruses in intestinal transplantation; UNMC experience

Presenter: Oana, Majorant, Omaha, United States
Authors: Oana Majorant, Fang Qiu, Andre Kalil, Alan Langnas, Natasha Wilson, David Mercer, Diana Florescu

Adenoviruses in intestinal transplantation; UNMC experience

Oana Majorant1, Fang Qiu1, Andre C. Kalil1, Alan Langnas2, Natasha Wilson1, David Mercer2, Diana F. Florescu1.

1Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, United States; 2Transplantation Surgery, University of Nebraska Medical Center, Omaha, NE, United States

Background: During the past few decades, adenoviruses (AdV) have emerged as important pathogens in the intestinal transplant (IT) recipients. The aim of the study was to assess the risk factors for AdV disease and compare outcomes in the IT patients with AdV disease versus AdV asymptomatic infection.

Methods: Retrospective study of recipients who received a transplant that included intestine and tested positive for AdV between January 1st 2004 and March 12th 2014. The patients were divided in 2 groups: AdV asymptomatic infections and AdV disease. Wilcoxon rank – sum was used for continuous variables and chi – square tests or Fisher exact tests for the categorical variables. Survival was analyzed by Kaplan–Meyer method and log–rank tests.

Results: 81 IT recipients were included, with the mean age of 4.72 years (SD 9.97); 49.38% were males; 22.22 % of the patients were diagnosed with AdV disease. Allograft types: 74.07 % of the patients underwent multivisceral (liver/small bowel/pancreas) transplant and 25.93% of the cases were small bowel. 43.21% of the recipients were cytomegalovirus (CMV) sero-positive.

Median time from transplant to AdV positive testing was 213 days (4–2653 days) in the asymptomatic infection group and 107.5 days (11–1649 days) in the AdV– disease group.

Table 1 presents the risk factors for AdV disease vs. asymptomatic infection

Table 2 describes the outcomes of the two groups.

Conclusion: There was a statistically significant higher mortality in the AdV disease group compared to the asymptomatic AdV infection group, suggesting that AdV may play a role in the outcomes of the IT recipients.

[1] 1. D. F. Florescu, J.A Hoffmann and the AST Infectious Diseases Community of Practice: Adenovirus in Solid Organ Transplantation American Journal of Transplantation 2013; 13:206 – 211
[2] 2. Rebecca J Pinchoff, Stuart Kaufman et al: Adenovirus infection in Pediatric Small bowel transplantation recipients Transplantation. 2003 Jul 15;76(1):183-9
[3] 3. Diana F. Florescu, Monirul K. Islam et al: Adenovirus infection in Pediatric Small Bowel Transplant Recipients Transplantation 2010 Jul 27; 90(2):198-204
[4] 4. J.A Hoffman Adenoviral disease in pediatric solid organ transplant recipients Pediatr. Transplantation 2006: 10: 17 – 25
[5] 5. Gwenn E. McLaughlin, Spiros Delis, Lutifat Kashimawo, G. Patricia Cantwell et al : Adenovirus Infection in Pediatric Liver and Intestinal Transplant Recipients: Utility of DNA detection by PCR American Journal of Transplantation 2003; 3: 224 – 228
[6] 6. Mariana Parizhskaya, Janet Walpusk et al: Enteric Adenovirus Infection in Pediatric Small Bowel Transplant Recipients Pediatric and Developmental Pathology 4, 122 – 128, 2001


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada